Article

Therapeutic Potential of Oral Everolimus for Facial Angiofi-bromas in Pediatric Tuberous Sclerosis Complex: A Case-Based Analysis of Efficacy

2024-11-18

Abstract excerpt

<h4>Background: </h4> Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by mutations in the TSC1 and TSC2 genes, leading to dysregulation of the mammalian target of rapamycin (mTOR) pathway. This dysregulation results in the development of benign tumors across multiple organ systems and poses significant neurodevelopmental challenges. The clinical manifestations of TSC vary w...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1d856f35-89dc-5ca3-af8b-02a05472caa6
DOI: 10.20944/preprints202411.1320.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Potential of Oral Everolimus for Facial Angiofi-bromas in Pediatric Tuberous Sclerosis Complex: A Case-Based Analysis of EfficacyDOI 10.20944/preprints202411.1320.v1Read

Tuberous sclerosis complex.Semantic proximity Read

Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practiceSemantic proximity Read

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis ComplexSemantic proximity Read

mTOR Inhibitors in Tuberous Sclerosis ComplexSemantic proximity Read

Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complexSemantic proximity Read

Characterization and Management of Facial Angiofibroma Related to Tuberous Sclerosis Complex in the United States: Retrospective Analysis of the Natural History DatabaseSemantic proximity Read

Tuberous sclerosis complex: advances in diagnosis, genetics, and management.Semantic proximity Read

Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.Semantic proximity Read

TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patientsSemantic proximity Read

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosisSemantic proximity Read

New developments in the neurobiology of the tuberous sclerosis complexSemantic proximity Read

Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.Semantic proximity Read